J Neurol Surg A Cent Eur Neurosurg 2016; 77(04): 283-290
DOI: 10.1055/s-0035-1571162
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Diagnostic Value of Magnetic Resonance Spectroscopy Compared with Stereotactic Biopsy of Intra-axial Brain Lesions

Osama Abdelaziz
1   Department of Neurosurgery, Alexandria University, Alexandria, Egypt
,
Mohamed Eshra
1   Department of Neurosurgery, Alexandria University, Alexandria, Egypt
,
Ahmed Belal
1   Department of Neurosurgery, Alexandria University, Alexandria, Egypt
,
Mohamed Elshafei
2   Department of Diagnostic Radiology, Alexandria University, Alexandria, Egypt
› Institutsangaben
Weitere Informationen

Publikationsverlauf

13. Mai 2015

22. Oktober 2015

Publikationsdatum:
02. März 2016 (online)

Abstract

Background Magnetic resonance spectroscopy (MRS) is usually added to conventional magnetic resonance imaging (MRI) to refine the diagnosis of different brain lesions. Stereotactic brain biopsy is a well-established method to obtain tissues for histopathologic examination. The purpose of the study is to compare the diagnostic yields of MRS and stereotactic biopsy in the characterization of brain lesions.

Material and Methods A prospective study conducted on 27 consecutive patients presenting with multifocal, diffuse, as well as deeply seated intra-axial brain lesions. All patients had both brain MRI and MRS prior to stereotactic biopsy. Histopathologic examinations of the obtained tissue specimens, using appropriate stains including immunostains, were performed.

Results MRS diagnosed neoplastic brain lesions in 15 cases (56%) and nonneoplastic brain lesions in 12 (44%). Correlation between the preoperative diagnosis by MRS and the histopathologic diagnosis following stereotactic biopsy of either a neoplastic or nonneoplastic lesion revealed matching in 25 of 27 cases (sensitivity 88%; specificity 100%). Within the group of cases (n = 15) diagnosed preoperatively by MRS as neoplastic, 12 patients were diagnosed with brain gliomas of different grades. The MRS grading of gliomas exactly matched the histopathologic grading following stereotactic biopsy in 10 of the 12 cases (sensitivity 89%; specificity 67%).

Conclusions MRS is a useful addition to the management armamentarium, providing molecular information that assists in the characterization of various brain lesions. Multivoxel MRS may increase the diagnostic yield of stereotactic biopsy by guidance to target the higher choline and lower N-acetylaspartate areas, expected to have greater tumor activity.

 
  • References

  • 1 Kaeser MA, Scali F, Lanzisera FP, Bub GA, Kettner NW. Tumefactive multiple sclerosis: an uncommon diagnostic challenge. J Chiropr Med 2011; 10 (1) 29-35
  • 2 Hourani R, Brant LJ, Rizk T, Weingart JD, Barker PB, Horská A. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults?. AJNR Am J Neuroradiol 2008; 29 (2) 366-372
  • 3 Fan G. Comments and controversies: magnetic resonance spectroscopy and gliomas. Cancer Imaging 2006; 6: 113-115
  • 4 Runge VM, Muroff LR, Jinkins JR. Central nervous system: review of clinical use of contrast media. Top Magn Reson Imaging 2001; 12 (4) 231-263
  • 5 Iwadate Y, Sakaida T, Hiwasa T , et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004; 64 (7) 2496-2501
  • 6 Pinker K, Stadlbauer A, Bogner W, Gruber S, Helbich TH. Molecular imaging of cancer: MR spectroscopy and beyond. Eur J Radiol 2012; 81 (3) 566-577
  • 7 Mullins ME. MR spectroscopy: truly molecular imaging; past, present and future. Neuroimaging Clin N Am 2006; 16 (4) 605-618 , viii
  • 8 Castillo M. Neuroimaging and cartography: mapping brain tumors. AJNR Am J Neuroradiol 2001; 22 (4) 597-598
  • 9 Qayyum A. MR spectroscopy of the liver: principles and clinical applications. Radiographics 2009; 29 (6) 1653-1664
  • 10 Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 2009; 64 (1) 12-21
  • 11 Moorthy RK, Rajshekhar V. Isolated ring-enhancing lesion of the brainstem in a patient with cyanotic heart disease: role of stereotactic intervention. Neurol India 2003; 51 (3) 404-406
  • 12 Setzer M, Herminghaus S, Marquardt G , et al. Diagnostic impact of proton MR-spectroscopy versus image-guided stereotactic biopsy. Acta Neurochir (Wien) 2007; 149 (4) 379-386
  • 13 Mittler MA, Walters BC, Stopa EG. Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg 1996; 85 (6) 1091-1094
  • 14 Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60 (3) 166-193
  • 15 Brandes AA, Franceschi E. New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology. Expert Rev Anticancer Ther 2006; 6 (8) 1129-1131
  • 16 Noda SE, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A. Molecular advances of brain tumors in radiation oncology. Semin Radiat Oncol 2009; 19 (3) 171-178
  • 17 Faria AV, Reis F, Zanardi VA, Menezes JR, Cendes F. The pattern of proton magnetic resonance spectroscopy in non-neoplastic encephalic lesions. Arq Neuropsiquiatr 2004; 62 (2B): 429-436
  • 18 Tate AR, Underwood J, Acosta DM , et al. Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 2006; 19 (4) 411-434
  • 19 Herminghaus S, Pilatus U, Möller-Hartmann W , et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002; 15 (6) 385-392
  • 20 Nelson SJ, Graves E, Pirzkall A , et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002; 16 (4) 464-476
  • 21 McKnight TR, von dem Bussche MH, Vigneron DB , et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97 (4) 794-802
  • 22 Möller-Hartmann W, Herminghaus S, Krings T , et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44 (5) 371-381
  • 23 Floeth FW, Pauleit D, Wittsack HJ , et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 2005; 102 (2) 318-327
  • 24 Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222 (3) 715-721
  • 25 Smith JK, Castillo M, Kwock L. MR spectroscopy of brain tumors. Magn Reson Imaging Clin N Am 2003; 11 (3) 415-429 , v–vi
  • 26 Weybright P, Sundgren PC, Maly P , et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005; 185 (6) 1471-1476
  • 27 Zeng QS, Li CF, Liu H, Zhen JH, Feng DC. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 2007; 68 (1) 151-158
  • 28 Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009; 192 (2) W45-52
  • 29 Law M, Yang S, Wang H , et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24 (10) 1989-1998
  • 30 Herminghaus S, Dierks T, Pilatus U , et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003; 98 (1) 74-81